REG - EnSilica PLC - New Contract Wins and Programme Upgrades

EnSilicaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260310:nRSJ9447Va&default-theme=true

RNS Number : 9447V  EnSilica PLC  10 March 2026

THIS ANNOUNCMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK LAW BY VIRTUE
OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR") AND IS DISCLOSED IN
ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF MAR

 

10 March 2026

 

EnSilica plc

("EnSilica", the "Company" or the "Group")

 

New Contract Wins and Programme Upgrades

 

EnSilica plc (AIM: ENSI), a leading fabless, application-specific chipmaker,
is pleased to provide an update on recent contract wins and programme
upgrades, which continues to underpin the Company's mid-term outlook.

 

New Contract Win for Life-Science Analysis Systems

 

EnSilica has secured a design implementation and manufacturing contract with a
leading UK publicly quoted life-sciences technology company.

 

Under this contract win, EnSilica will provide semiconductor design
implementation expertise alongside tape-out management and wafer manufacturing
services for a next-generation chip used within advanced life-science analysis
systems. The semiconductor will be manufactured at a leading semiconductor
foundry, with EnSilica providing the customer with direct access and technical
support.

 

The initial contract value, including engineering services and prototype wafer
supply, is approximately US$1.6 million with material revenue contributions
commencing in the financial year ending 31 May 2027 ("FY 2027"), with the
potential of future additional long-term revenue from future production wafer
supply.

 

New Contract for Wireless Healthcare ASIC Feasibility Study

 

EnSilica has been awarded a fully funded feasibility study contract by a U.S.
healthcare technology company to develop a wireless biosensing and therapeutic
controller ASIC. The end application uses cloud-based AI to support treatment
for chronic conditions.

 

The feasibility study has a value of approximately US$200,000 and leverages
EnSilica's existing eSi-Sense healthcare technology platform. The study is
scheduled to commence in May 2026 and will run for 3 months. A successful
study is expected to lead to a multi-million-dollar design and supply
agreement.

 

Upgrade and Extension of Existing Automotive ASIC Programme

 

The Company is pleased to report an increase in forecast demand for calendar
years 2026 to 2028 for its existing automotive ASIC contract with a premier
global OEM brand. This increase in volumes is expected to generate additional
revenues in excess of US$4 million over calendar years 2026 and 2028.

 

The Company is also pleased to report that production volumes for this
programme are now expected to extend beyond 2030, increasing the estimated
lifetime value of the programme to in excess of the previously forecast value
of US$40 million.

 

Outlook

 

These new engagements and programme updates further strengthen the Company's
confidence in achieving market consensus forecasts for the current financial
year ending 31 May 2026 ("FY 2026") as well as FY 2027.

 

The Board remains confident of delivering a substantial increase in revenues
and EBITDA profitability for FY 2026 and reiterates its current guidance for
FY 2026 of revenues of between £28 million to £30 million and EBITDA profits
of between £3.5 million and £4.5 million.

 

Ian Lankshear, Chief Executive Officer of EnSilica, commented:

 

"These new contract wins and programme upgrades reflect the continued demand
for EnSilica's capabilities across our key growth markets, including multiple
engagements across the satellite communications arena.

 

This encouraging momentum further strengthens our revenue visibility and
supports the Board's confidence in the Company delivering sustained revenue
growth and generating near-term cash-generation."

 

 EnSilica plc                                                           via Vigo Consulting

 Ian Lankshear, Chief Executive Officer                                 +44 (0)20 7390 0233

 Kristoff Rademan, Chief Financial Officer

 www.ensilica.com (http://www.ensilica.com)

 Allenby Capital Limited (Nominated Adviser & Joint Broker)

 Jeremy Porter / Vivek Bhardwaj (Corporate Finance)                     +44 (0)20 3328 5656

 Joscelin Pinnington / Tony Quirke (Sales & Corporate Broking)          info@allenbycapital.com (mailto:info@allenbycapital.com)

 Panmure Liberum Limited (Joint Broker)

 Edward Mansfield / Will King / Phoebe Bunce                            +44 (0)20 3100 2000

 Vigo Consulting (Investor & Financial Public Relations)                +44 (0)20 7390 0233

 Jeremy Garcia/ Safia Colebrook                                         ensilica@vigoconsulting.com (mailto:visum@vigoconsulting.com)

 

The person responsible for arranging release of this announcement on behalf of
the Company is Ian Lankshear, Chief Executive Officer.

 

About EnSilica plc

EnSilica is a fabless, application-specific chipmaker, combining deep domain
and system-level expertise with world-class capability in RF, mmWave,
mixed-signal and complex digital IC design. The Company serves customers
across the space and communications, industrial, automotive and healthcare
markets, where safety and security and reliability are critical.

A growing portfolio of reusable IP and silicon platforms underpins a
repeatable, scalable delivery model, reducing development risk, cost and time
to market while supporting long-term supply revenues. EnSilica has a strong
track record of delivering production-proven silicon to demanding industry
standards. Headquartered near Oxford, UK, the Company operates design centres
across the UK, India, Brazil and Hungary.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKCBKCBKDCNK



            Copyright 2019 Regulatory News Service, all rights reserved